Ionis Pharmaceuticals traded at $40.02 this Friday January 27th, increasing $0.64 or 1.63 percent since the previous trading session. Looking back, over the last four weeks, Ionis Pharmaceuticals gained 7.81 percent. Over the last 12 months, its price rose by 26.33 percent. Looking ahead, we forecast Ionis Pharmaceuticals to be priced at 38.71 by the end of this quarter and at 35.02 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
40.02
Daily Change
1.63%
Yearly
26.33%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Astellas Pharma 1,913.50 -25.00 -1.29% 3.40%
Agios Pharmaceuticals 30.75 0.03 0.10% 2.30%
Alnylam Pharmaceuticals 231.37 -0.22 -0.10% 75.16%
Arrowhead Research 33.61 0.33 0.99% -32.90%
BioCryst Pharmaceuticals 10.58 -0.20 -1.86% -28.85%
Bluebird Bio 6.28 0.05 0.80% -16.60%
BioMarin Pharmaceutical 117.27 0.29 0.25% 36.11%
Esperion Therapeutics 6.68 0.03 0.45% 64.13%
Exelixis 17.47 -0.24 -1.36% -1.69%
Halozyme Therapeutics 50.71 -2.57 -4.82% 55.74%
Intercept Pharmaceuticals 18.40 0.03 0.16% 18.40%
Moderna Inc 189.35 -3.89 -2.01% 18.74%
Mirati Therapeutics 53.09 2.03 3.98% -53.00%
Neurocrine Biosciences 108.25 -0.13 -0.12% 41.08%
Nektar Therapeutics 2.61 0.15 6.10% -75.49%
Novartis 82.85 0.27 0.33% 3.39%
Omeros 2.70 0.17 6.72% -52.04%
Pfizer 43.79 -0.46 -1.04% -19.40%
PTC Therapeutics 46.25 0.26 0.57% 18.50%
Ultragenyx Pharmaceutical 43.72 -0.42 -0.95% -33.76%
Regeneron Pharmaceuticals 742.83 0.53 0.07% 18.87%
Roche Holding 289.10 -0.25 -0.09% -19.00%
Sarepta Therapeutics 122.89 -1.58 -1.27% 76.34%
Vertex Pharmaceuticals 321.45 0.43 0.13% 32.27%


Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).